One year after the new ESC/EAS dyslipidemia guidelines
Video navigation menu
- PCSK9 mAb: Efficacy and safety 02:39
- Fundamental principles for LDL-lowering therapy 03:37
- CV risk categories 05:13
- LDL-c lipid-lowering treatment goals and recommendations 06:47
- Future prospects in lipid-lowering therapies 12:29
This presentation by Prof. François Mach, MD was part of the EBAC-accredited symposium "PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities" held during the virtual ESC Congress 2020.
Prof. François Mach, Head of the Cardiology Division, Geneva University Hospital, Geneva, Switzerland, and Professor of Cardiology, Geneva University Medical School, Geneva, Switzerland.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Sanofi and Amgen.
This is available as accredited online CME for members. Click the button below to enroll:Enroll